The U.S. Food and Drug Administration (FDA) on June 16 issued a series of warning letters to telehealth companies for promoting compounded weight-loss and diabetes drugs with “false and misleading” claims.
The agency said it had sent 25 warning letters to telehealth companies such as Ready Med, Maximus Health, and Medica Weight Loss over claims that their compounded GLP-1 drugs had been evaluated for safety.
“Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of consistent quality,” the FDA said in a post on X.
According to the letters, the companies had falsely claimed on their websites that their compounded versions of semaglutide and tirzepatide products were FDA-approved or had been evaluated for safety, while some displayed misleading labels suggesting they compounded those drugs….